Elevation Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Elevation Oncology
ELEV Stock  USD 0.67  0.05  8.06%   
Elevation Oncology financial statements provide useful quarterly and yearly information to potential Elevation Oncology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Elevation Oncology financial statements helps investors assess Elevation Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Elevation Oncology's valuation are summarized below:
Market Capitalization
39.4 M
Earnings Share
(0.80)
There are over one hundred nine available fundamental signals for Elevation Oncology, which can be analyzed over time and compared to other ratios. All traders should should verify Elevation Oncology's prevailing fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to drop to about 20 M in 2025. Enterprise Value is likely to climb to about (894 K) in 2025
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.3 K, Interest Expense of 5 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.32. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
  
Check out the analysis of Elevation Oncology Correlation against competitors.
For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

Elevation Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets91.4 M102.5 M39.2 M
Slightly volatile
Other Current Liabilities3.8 M4.2 M1.7 M
Slightly volatile
Total Current Liabilities7.9 M4.8 M3.4 M
Slightly volatile
Accounts Payable553.9 K583 K1.5 M
Slightly volatile
Cash71 M56.6 M29.1 M
Slightly volatile
Cash And Short Term Investments88.2 M95.6 M37.5 M
Slightly volatile
Common Stock Shares Outstanding28.2 M39.2 M25.6 M
Slightly volatile
Liabilities And Stockholders Equity91.4 M102.5 M39.2 M
Slightly volatile
Non Current Liabilities Total26.2 M27.1 M17.6 M
Slightly volatile
Other Current Assets3.4 M5.6 M1.6 M
Slightly volatile
Total Liabilities32 M30.9 M20.8 M
Slightly volatile
Total Current Assets90.9 M101.2 M38.9 M
Slightly volatile
Net Working Capital83 M96.4 M35.5 M
Slightly volatile
Other Liabilities1.7 K1.8 K11.3 K
Slightly volatile
Non Currrent Assets Other619 K1.2 M296.7 K
Slightly volatile
Other Assets1.091.15114.6 K
Pretty Stable
Non Current Liabilities Other1.7 K1.8 K11.3 K
Slightly volatile
Intangible Assets69.0367.8559.2425
Slightly volatile
Common Stock2.9 K4.6 K2.3 K
Slightly volatile
Property Plant Equipment74.8 K112.7 K52.5 K
Slightly volatile
Short and Long Term Debt Total32.8 M34.7 M30 M
Slightly volatile
Long Term Debt32.8 M34.7 M30 M
Slightly volatile
Common Stock Total Equity1.6 K1.8 K2 K
Slightly volatile
Long Term Debt Total23.5 M26.5 M28.9 M
Slightly volatile
Capital Surpluse159.6 M179.5 M195.8 M
Slightly volatile

Elevation Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization33.3 K35.1 K2.2 M
Slightly volatile
Selling General Administrative9.2 M17.1 M4.7 M
Slightly volatile
Selling And Marketing Expenses33.3 K35.1 K353.5 K
Slightly volatile
Other Operating Expenses42.9 M52.3 M21.5 M
Slightly volatile
Research Development32.7 M29.2 M16.2 M
Slightly volatile
Total Operating Expenses42.9 M52.3 M21.5 M
Slightly volatile
Cost Of Revenue27.2 K44.9 K20.1 K
Slightly volatile
Reconciled Depreciation27.2 K44.9 K20.1 K
Slightly volatile
Interest Income2.7 M4.5 M1.5 M
Slightly volatile

Elevation Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings23.9 M26.6 M29.3 M
Slightly volatile
Stock Based Compensation4 M3.8 M1 M
Slightly volatile
Depreciation25.7 K44.9 K21.8 K
Slightly volatile
Total Cash From Financing Activities59.8 M55.2 M28.2 M
Slightly volatile
End Period Cash Flow71 M56.6 M29.1 M
Slightly volatile
Change To Netincome4.2 M4 M1.1 M
Slightly volatile
Begin Period Cash Flow75.2 M52.8 M26.2 M
Slightly volatile
Issuance Of Capital Stock56.1 M41.9 M80 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation4.363.664.3526
Slightly volatile
Payables Turnover0.07270.06920.016
Slightly volatile
Cash Per Share2.572.191.341
Slightly volatile
Days Payables Outstanding110.3 K98.9 K109.7 K
Slightly volatile
Income Quality0.751.110.9317
Pretty Stable
Intangibles To Total Assets0.00.00.0
Slightly volatile
Net Debt To EBITDA0.50.530.8621
Slightly volatile
Current Ratio20.0519.17.9541
Slightly volatile
Graham Number6.366.273.935
Slightly volatile
Debt To Equity0.640.630.6015
Pretty Stable
Capex Per Share0.00270.00330.0031
Slightly volatile
Interest Debt Per Share1.261.161.2588
Slightly volatile
Debt To Assets0.260.30.3101
Slightly volatile
Days Of Payables Outstanding110.3 K98.9 K109.7 K
Slightly volatile
Ebt Per Ebit0.80.90.9814
Slightly volatile
Long Term Debt To Capitalization0.40.410.3776
Slightly volatile
Total Debt To Capitalization0.40.410.3776
Slightly volatile
Debt Equity Ratio0.640.630.6015
Pretty Stable
Quick Ratio20.0519.17.9541
Slightly volatile
Net Income Per E B T0.80.90.9815
Slightly volatile
Cash Ratio7.3710.695.6476
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0198
Slightly volatile
Debt Ratio0.260.30.3101
Slightly volatile

Elevation Oncology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20 M21 M200.5 M
Slightly volatile

Elevation Fundamental Market Drivers

Cash And Short Term Investments83.1 M

Elevation Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Elevation Oncology Financial Statements

Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue44.9 K27.2 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY